Lost in migration

Nature Biotechnology

Volumn 28, Issue 3, 2010, Pages 214-229

  MacK, George S ^a   Marshall, Andrew ^a  

^a Nature Biotechnology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADH 1; AMG 386; AMG 479; ANTINEOPLASTIC AGENT; ARQ 197; DALOTUZUMAB; DASATINIB; DENOSUMAB; FIBROBLAST GROWTH FACTOR; FORETINIB; GCD 0449; INTETUMUMAB; MESUPRON; MGCD 265; MK 0646; ODANACATIB; OSI 906; PANITUMUMAB; PI 88; PLASMINOGEN ACTIVATOR INHIBITOR; RILOTUMUMAB; SOMATOMEDIN; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VOLOCIXIMAB; WX UK 1; XL 184; ZOLEDRONIC ACID;

ADVANCED CANCER; BACTERIAL COLONIZATION; BASAL CELL CARCINOMA; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CARCINOGENESIS; CIRCULATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG TARGETING; EARLY DIAGNOSIS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MIGRATION; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER;

ANIMALS; CELL HYPOXIA; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; WHOLE BODY IMAGING;

EID: 77749319354     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0310-214     Document Type: Review

References (29)

1. Klein, C. Nat. Rev. Cancer 9, 302-312 (2009).
2. Nguyen, D.X., Bos, P.D. & Massague, J. Nat. Rev. Cancer 9, 274-284 (2009).
3. Rudland, P.S. et al. Cancer Res. 60, 1595-1603 (2000).
4. Heiss, M.M. et al. Nat. Med. 1, 1035-1039 (1995).
5. Nakajima, S. et al. Clin. Cancer Res. 10, 4125-4133 (2004).
6. Talukder, A.H. et al. Clin. Cancer Res. 8, 3285-3289 (2002).
7. Huang, S. et al. Nature 461, 614-620 (2009).
8. Korc, M. et al. J. Clin. Invest. 118, 89-99 (2007).
9. Erler, J.T. et al. Cancer Cell 15, 35-44 (2009).
10. Maetzel, D. et al. Nat. Cell Biol. 11, 162-171 (2009).
11. Yamada, S. & Sugahara, K. Curr. Drug Discov. Technol. 5, 289-301 (2008).
12. Kang, S.Y. et al. Proc. Natl. Acad. Sci. USA 106, 12115-12120 (2009).
13. Ohtaki, T. et al. Nature 411, 613-617 (2001).
14. Fernández, C.A. et al. J. Urol. 182, 2188-2194 (2009).
15. Yang, J. et al. Proc. Natl. Acad. Sci. USA 106, 3913-3918 (2009).
16. Nagrath, S. et al. Nature 450, 1235-1239 (2007).
17. Chen, E.X. et al. J. Am. Med. Assoc. 292, 2150-2151 (2004).
18. Fidler, I.J. Cancer Res. 50, 6130-6138 (1990).
19. Hoffman, R.M. Invest. New Drugs 17, 343-359 (1999).
20. Chishima, T. et al. Proc. Natl. Acad. Sci. USA 94, 11573-11576 (1997).
21. Zijlsta, A. et al. Cancer Cell 13, 221-234 (2008).
22. Costa, F.F. Gene 357, 83-94 (2005).
23. Costa, F. F. Gene 386, 1-10 (2007).
24. Frank, N.Y. et al. J. Biol. Chem. 278, 47156-47165 (2003).
25. Frank, N.Y. et al. Cancer Res. 65, 4320-4333 (2005).
26. Quintana, E. et al. Nature 456, 593-598 (2008).
27. Psaila, B. & Lyden, D. Nat. Rev. Cancer 9, 285-293 (2009).
28. Katz, M.H. et al. Cancer Res. 64, 1828-1833 (2004).
29. Lodish, H. Molecular Cell Biology (New York, WH Freeman, 2003).